Litigation Details for Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2010)

Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2010)

Docket		Date Filed	2010-03-05
Court	District Court, S.D. New York	Date Terminated	2013-02-20
Cause	35:271 Patent Infringement	Assigned To	Richard Joseph Sullivan
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICALS INDUSTRIES LIMITED
Patents	6,043,230
Attorneys	Christopher P. Borello
Firms	Goodwin Procter, LLP (NYC), the New York Times Building
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-03-05				External link to document

Gilead Sciences v. Teva Pharmaceuticals USA, Inc. Litigation Summary, 1:10-cv-01796

Last updated: September 29, 2026

Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:10-cv-01796, was an ANDA patent dispute in the U.S. District Court for the District of Delaware involving Gilead’s HIV antiretroviral products and Teva’s proposed generic products. The case was resolved through a settlement rather than a reported merits judgment. The settlement permitted Teva to enter the U.S. market for certain Gilead antiretroviral products before full expiration of Gilead’s asserted patent rights, with reported entry no later than December 15, 2017.

What products and patents were involved in Gilead v. Teva?

The litigation concerned Gilead products containing tenofovir disoproxil fumarate, including Viread and combination products such as Truvada and Atripla. These products were protected through a portfolio covering the active pharmaceutical ingredient, nucleotide analog chemistry, prodrug forms, pharmaceutical compositions, and treatment methods.

Product and regulatory background

Product	Active ingredients	FDA approval	Commercial relevance
Viread	Tenofovir disoproxil fumarate	2001	Stand-alone tenofovir product
Truvada	Tenofovir disoproxil fumarate and emtricitabine	2004	HIV treatment and later HIV pre-exposure prophylaxis
Atripla	Efavirenz, emtricitabine, and tenofovir disoproxil fumarate	2006	Once-daily fixed-dose HIV regimen

The case was filed after Teva submitted an abbreviated new drug application seeking FDA approval for a generic version of a Gilead antiretroviral product. Teva’s ANDA filing likely included Paragraph IV certifications challenging one or more listed patents under the Hatch-Waxman Act. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification gives the branded manufacturer a statutory basis to file an infringement action under 35 U.S.C. § 271(e)(2).

Patent portfolio

Gilead’s tenofovir portfolio included patents directed to:

• Nucleotide analog compounds;
• Tenofovir and related phosphonate chemistry;
• Prodrug forms, including tenofovir disoproxil;
• Salt and fumarate forms;
• Pharmaceutical compositions;
• Methods of treating HIV infection.

The central commercial patent issue was the timing of generic entry. Gilead’s foundational tenofovir patents had expected expiration dates in the late 2010s, subject to patent-term adjustment, patent-term extension, pediatric exclusivity, and the specific claims asserted against Teva. The settlement avoided a judicial determination of whether the relevant claims were valid and infringed.

When did Gilead file the Delaware patent case?

Gilead filed the action in 2010 under Civil Action No. 1:10-cv-01796 in the District of Delaware. The complaint followed Teva’s ANDA challenge and triggered the statutory 30-month stay of FDA approval applicable to the challenged ANDA, unless the litigation was resolved earlier or the stay was otherwise terminated.

The case was part of a broader wave of ANDA litigation involving Gilead’s HIV franchise. Gilead used patents covering both the active molecule and the prodrug formulation to delay or control generic competition for Viread and combination products.

What was the litigation strategy?

Gilead’s litigation strategy relied on a layered patent estate rather than a single composition-of-matter patent. That structure gave Gilead several potential infringement theories:

1. Teva’s proposed generic active ingredient could infringe compound claims.
2. The proposed tenofovir disoproxil fumarate product could infringe prodrug or salt claims.
3. The generic tablet could infringe pharmaceutical-composition claims.
4. Teva’s proposed labeling could create method-of-use infringement exposure.

Teva’s principal strategy was to obtain FDA approval through Paragraph IV certifications and challenge the enforceability, validity, or scope of the asserted patents. A generic applicant commonly attacks a branded patent on obviousness, anticipation, lack of written description, lack of enablement, or claim construction grounds. The economic objective is to secure launch before the full commercial life of the brand product expires.

Was there a Paragraph IV challenge?

Yes. The case arose from an ANDA patent challenge, which ordinarily requires a Paragraph IV certification for each Orange Book-listed patent that the generic applicant seeks to avoid. The resulting patent action is an artificial act of infringement under the Hatch-Waxman framework.

A Paragraph IV filing creates both litigation risk and commercial leverage:

• The branded company can sue within 45 days to obtain the 30-month stay.
• The generic company can seek a first-filer advantage if it is the first qualifying Paragraph IV applicant.
• The parties can negotiate a launch date that may be earlier than the asserted patent expiration dates.
• The settlement can preserve some period of branded exclusivity while giving the generic company a defined market-entry date.

The public resolution of Gilead v. Teva did not produce a reported invalidity or infringement holding. The settlement therefore provides no judicial precedent on the ultimate validity or scope of the patents asserted in this docket.

What was the settlement outcome?

Gilead and Teva settled the litigation. Public company disclosures reported that Teva received a license to market generic versions of certain Gilead HIV products in the United States, with launch permitted no later than December 15, 2017. The agreement may also have allowed earlier entry under specified circumstances, such as a third-party generic launch or other contractually defined events.

The settlement converted uncertain litigation exposure into a fixed launch framework. For Gilead, the arrangement preserved branded sales through a negotiated date and avoided the risk of an adverse patent judgment. For Teva, the agreement provided a defined commercial pathway without requiring a full trial and appellate process.

Because settlement terms were not fully public, the docket does not establish:

• The precise allocation of royalties;
• Whether Teva received an exclusive or nonexclusive license;
• The exact patents released;
• Whether Teva received manufacturing or supply rights;
• The conditions for entry before December 15, 2017;
• The treatment of later-approved indications, including PrEP.

What was the Orange Book status of the Gilead products?

Gilead’s HIV products were subject to Orange Book listings for patents covering drug substances, drug products, and methods of use. Orange Book-listed patents can generate Hatch-Waxman litigation when a generic applicant files a certification challenging those patents.

The commercial significance of the listings differed by product:

Patent category	Typical protection	Generic-entry effect
Drug-substance patent	Tenofovir or related compound	Potentially blocks products using the claimed molecule
Drug-product patent	Tablet, salt, prodrug, or formulation	May block the approved dosage form
Method-of-use patent	HIV treatment or prevention indication	May require a skinny label or create induced-infringement risk
Combination-product patent	Fixed-dose combination	May affect Truvada or Atripla substitutes

The Orange Book status must be evaluated by product and approval number. A patent settlement covering Viread does not automatically resolve every patent claim applicable to Truvada, Atripla, or later indications.

How strong was Gilead’s patent estate?

Gilead’s estate was commercially strong because it combined early compound and prodrug patents with formulation and combination-product rights. The settlement also indicates that both parties faced material litigation risk: Gilead accepted licensed entry, while Teva accepted a delayed launch rather than pursuing immediate market entry through trial and appeal.

The estate’s principal strengths were:

• Broad coverage around tenofovir chemistry;
• Commercial importance of the tenofovir disoproxil fumarate prodrug;
• Multiple marketed products relying on the same active ingredient;
• FDA-approved combination products with substantial prescription volume;
• Potential method-of-use protection tied to HIV treatment.

The principal weaknesses were the age of the foundational patents and the vulnerability of narrower formulation or method claims to validity challenges. Once a compound patent approaches expiration, later patents must provide meaningful, enforceable coverage of the actual generic product and its proposed labeling.

What generic entry risks existed after settlement?

The settlement reduced the probability of an immediate at-risk launch but created a defined future erosion event. The main scenarios were:

Authorized or licensed generic entry

Teva could enter under the negotiated license on or before the agreed date. This was the most predictable scenario and allowed Gilead to manage the transition.

At-risk launch

Teva could have launched before final resolution if it accepted potential damages exposure and obtained favorable procedural conditions. An at-risk launch would have exposed Gilead to a possible preliminary-injunction application and Teva to substantial damages if infringement were ultimately established.

Third-party generic entry

The agreement could permit earlier Teva entry if another generic manufacturer launched first or if another event impaired Gilead’s exclusivity. Such clauses are common in negotiated ANDA settlements.

Product-specific entry

Generic entry could occur at different times for Viread, Truvada, and Atripla depending on the patents listed for each product, the scope of the license, and the regulatory status of the relevant ANDA.

Which companies challenged Gilead’s HIV franchise?

Teva was one of several generic companies that pursued ANDA strategies against Gilead’s antiretroviral products. Other Gilead patent disputes involved companies such as Mylan, Watson, Apotex, and Natco, depending on the specific product and patent family.

The competitive risk was greater for products containing tenofovir disoproxil fumarate because the same active ingredient supported multiple branded products. Generic competition against a single component could affect Viread, Truvada, and Atripla economics, although fixed-dose combination products could remain separately protected.

Did the case affect later PrEP competition?

The 2010 case predated the major commercial expansion of Truvada for HIV pre-exposure prophylaxis. The later PrEP market raised separate questions involving indication-specific labeling, method-of-use patents, and the relationship between treatment and prevention claims.

Gilead’s later dispute with Teva and other generic companies over Truvada and PrEP-related rights was distinct from the original 1:10-cv-01796 litigation. A settlement concerning earlier HIV-treatment products should not be treated as a complete resolution of every later patent dispute involving Truvada’s PrEP indication.

What was the business impact of the settlement?

The settlement protected Gilead from an immediate loss of exclusivity while establishing a fixed timetable for generic erosion. The commercial impact depended on:

• U.S. sales of Viread, Truvada, and Atripla;
• The number of generic entrants at the licensed launch date;
• Whether Teva launched a single-product or multi-product portfolio;
• Substitution rules and payer contracts;
• The extent to which patients moved to newer tenofovir alafenamide products;
• The effect of future combination therapies.

The agreement also reduced litigation costs and removed the binary outcome associated with a patent trial. For investors, the key exposure was the transition from protected pricing to multi-source generic competition after the negotiated entry date.

What is the current litigation status?

The case was resolved by settlement and is not a live merits dispute. There was no final reported judgment establishing that Teva infringed the asserted patents, and no Federal Circuit opinion from this docket determining the validity of the relevant Gilead claims.

The settlement should therefore be analyzed as a market-access agreement rather than as a precedential patent decision.

Key Takeaways

• Gilead v. Teva, No. 1:10-cv-01796, was a Delaware ANDA case involving Gilead’s tenofovir-based HIV products.
• The dispute arose from Teva’s Paragraph IV challenge to Gilead patent rights.
• The asserted portfolio covered tenofovir chemistry, prodrug forms, formulations, combinations, and treatment methods.
• The case ended in settlement rather than a reported trial judgment.
• Public disclosures reported Teva generic entry no later than December 15, 2017.
• The settlement reduced immediate litigation risk but established a future generic-erosion date.
• The case did not resolve every later patent issue involving Truvada, PrEP, or newer tenofovir formulations.
• No reported decision from this docket establishes the ultimate validity or infringement of the asserted patents.

FAQs

Did Gilead win Gilead v. Teva?

Neither party obtained a reported merits victory. The litigation ended in a negotiated settlement that delayed generic entry while granting Teva a future license.

Did Teva launch a generic version of Truvada?

Teva received rights to market generic versions of certain Gilead antiretroviral products under the settlement framework. Product-specific launch timing depended on the relevant license and FDA approval status.

Was the case about tenofovir alafenamide?

No. The litigation concerned Gilead’s earlier tenofovir disoproxil fumarate franchise. Tenofovir alafenamide products, including Descovy and Biktarvy-related products, involve separate patent estates and regulatory issues.

Did the settlement invalidate Gilead patents?

No. A settlement is not an invalidity ruling. The asserted patents remained unresolved on the merits unless separately invalidated, expired, or disclaimed.

Could Teva enter before the agreed date?

The settlement reportedly allowed entry no later than December 15, 2017 and may have included provisions permitting earlier entry under defined circumstances. The complete contractual conditions were not publicly disclosed.

References

1. United States District Court for the District of Delaware. (2010). Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:10-cv-01796. PACER docket record.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. Gilead Sciences, Inc. (2013). Form 10-K for the fiscal year ended December 31, 2012. U.S. Securities and Exchange Commission.

4. Gilead Sciences, Inc. (2014). Form 10-K for the fiscal year ended December 31, 2013. U.S. Securities and Exchange Commission.

5. U.S. Food and Drug Administration. (2001). Viread approval history and prescribing information.

6. U.S. Food and Drug Administration. (2004). Truvada approval history and prescribing information.